UBS Group Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $188.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective lifted by UBS Group from $173.00 to $188.00 in a research report sent to investors on Tuesday morning. UBS Group currently has a buy rating on the biotechnology company’s stock.

SRPT has been the topic of a number of other research reports. Cantor Fitzgerald cut their target price on shares of Sarepta Therapeutics from $167.00 to $152.00 and set a neutral rating on the stock in a research report on Thursday, August 8th. Evercore ISI raised shares of Sarepta Therapeutics from an in-line rating to an outperform rating and reduced their price objective for the stock from $185.00 to $179.00 in a research note on Thursday, August 8th. Royal Bank of Canada restated an outperform rating and set a $181.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 6th. Needham & Company LLC reiterated a buy rating and issued a $235.00 price target on shares of Sarepta Therapeutics in a report on Thursday, June 27th. Finally, Leerink Partners upped their price objective on Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an outperform rating in a research note on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of Moderate Buy and an average price target of $187.39.

Sarepta Therapeutics Stock Up 1.7 %

Shares of NASDAQ SRPT opened at $127.10 on Tuesday. The stock has a 50 day moving average price of $138.26 and a 200 day moving average price of $132.61. The firm has a market capitalization of $12.01 billion, a price-to-earnings ratio of 1,155.45 and a beta of 0.81. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business’s revenue was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.27) EPS. Sell-side analysts expect that Sarepta Therapeutics will post 1.47 earnings per share for the current year.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total value of $6,295,840.77. Following the sale, the executive vice president now directly owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 52,801 shares of company stock valued at $8,399,586. Company insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Principal Securities Inc. acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $26,000. Mather Group LLC. purchased a new stake in Sarepta Therapeutics during the first quarter worth $28,000. Riggs Asset Managment Co. Inc. grew its position in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the period. Innealta Capital LLC purchased a new position in Sarepta Therapeutics in the second quarter valued at $31,000. Finally, New Covenant Trust Company N.A. acquired a new position in shares of Sarepta Therapeutics in the first quarter worth about $32,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.